Eidos Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch EIDX and buy or sell other stocks, ETFs, and their options commission-free!About EIDX
Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR.
CEONeil Kumar, PhD
CEONeil Kumar, PhD
Employees—
Employees—
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2013
Founded2013
Employees—
Employees—
EIDX Key Statistics
Market cap4.75B
Market cap4.75B
Price-Earnings ratio-46.10
Price-Earnings ratio-46.10
Dividend yield—
Dividend yield—
Average volume138.46K
Average volume138.46K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$132.54
52 Week high$132.54
52 Week low$28.39
52 Week low$28.39
Stock Snapshot
With a market cap of 4.75B, Eidos Therapeutics(EIDX) trades at $122.21. The stock has a price-to-earnings ratio of -46.10.
Eidos Therapeutics(EIDX) stock opened on 2025-12-17 at —. The price climbed to — and dipped to —.
Eidos Therapeutics(EIDX) shares are trading with a volume of 0, against a daily average of 138.46K.
In the last year, Eidos Therapeutics(EIDX) shares hit a 52-week high of $132.54 and a 52-week low of $28.39.
In the last year, Eidos Therapeutics(EIDX) shares hit a 52-week high of $132.54 and a 52-week low of $28.39.
People also own
Based on the portfolios of people who own EIDX. This list is generated using Robinhood data, and it’s not a recommendation.